Changes in regional ventilation-perfusion after artery graft ballooning in dialysis patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-center, observational pilot study that uses electrical impedance tomography to monitor regional ventilation and perfusion in real time around the time of percutaneous transluminal angioplasty for AVG thrombosis. Researchers will measure changes in V/Q matching, dead space, shunt fraction, and oxygenation at six time points from 10 minutes before the procedure to completion. The goal is to understand the immediate pulmonary physiological effects of small thrombus fragments entering the lungs during revascularization. Data will be analyzed with repeated-measures ANOVA or mixed-effects models to describe short-term trends and variability.

Why it matters

Who can join: the full rules

Inclusion Criteria

1. Age ≥ 18 years.
2. Diagnosis of end-stage renal disease receiving maintenance hemodialysis.
3. Documented AVG thrombosis requiring PTA.
4. Able to cooperate and tolerate EIT monitoring.
5. Provided written informed consent.

Exclusion Criteria

1. Severe respiratory failure incompatible with supine position.
2. Thoracic skin condition or deformity preventing EIT electrode placement.
3. Acute pulmonary embolism or acute pulmonary edema before procedure.
4. NYHA Class IV heart failure or hemodynamic instability.
5. Pregnancy or breastfeeding.
6. Any other circumstance judged unsuitable by investigator.

Where it's running

• The First Affiliated Hospital of Wannan Medical College (Yijishan Hospital of Wannan Medical College)
  Wuhu, China Recruiting

Study contacts

• Study coordinator: qiancheng xu, PhD
• Email: qianchengxu@wnmc.edu.cn
• Phone: +86-18297529106

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• How the body handles fosmanogepix in adults on dialysis

  This study tests how fosmanogepix behaves in the body and its safety in adults with end-stage kidney disease on dialysis, compared to people with normal kidney function.

  Recruiting at 2 sites Phase 1 Basilea Pharmaceutica · Orlando, Florida and 1 other locations · NCT07916181

• Coated Aldehyde Oxystarch to lower PBUTs in adults on dialysis

  This study tests whether a coated oral adsorbent called Coated Aldehyde Oxystarch (Xiqing) can lower protein-bound uremic toxins in adults on maintenance dialysis and checks its safety.

  Recruiting Peking University People's Hospital · Beijing · NCT07653711

• Four-hour pHA130 hemoadsorption with hemodialysis

  We will test whether using pHA130 hemoadsorption for 4 hours instead of 2 during regular dialysis removes more protein-bound toxins like indoxyl sulfate in people on maintenance hemodialysis.

  Recruiting Peking University People's Hospital · Beijing, Beijing Municipality · NCT07111260

• CRISPR-edited donor kidney transplant to reduce rejection risk

  This trial will see if donor kidneys edited with CRISPR to turn off key HLA genes can lower rejection in adults with end-stage kidney disease receiving transplants.

  Recruiting Phase 1/2 American Organ Transplant and Cancer Research Institute LLC · Beijing, Changping · NCT07053462

• Progressive muscle relaxation plus walking to reduce fatigue in adults on dialysis

  This program will try progressive muscle relaxation combined with regular walking to see if it reduces fatigue for adults receiving in-center hemodialysis.

  Recruiting University of Illinois Chicago · Chicago, Illinois · NCT07014111

• AP306 at fixed doses in adults on dialysis with high phosphate

  This trial tests if AP306, taken daily at different doses, can safely lower phosphate levels in adults on maintenance dialysis with hyperphosphatemia.

  Recruiting at 31 sites Phase 2 R1 Therapeutics · Huntsville, Alabama and 30 other locations · NCT06712654

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.